Genistein protects the kidney from cisplatin-induced injury

Area of Science:

• Nephrology
• Molecular Biology
• Pharmacology

Background:

• Cisplatin is a widely used chemotherapy drug associated with significant kidney damage (nephrotoxicity).
• Oxidative stress and inflammatory responses are key mechanisms driving cisplatin-induced renal injury.
• Existing treatments for nephrotoxicity are limited, highlighting the need for protective strategies.

Purpose of the Study:

• To investigate the protective effects of genistein against cisplatin-induced nephrotoxicity in preclinical models.
• To elucidate the molecular mechanisms underlying genistein's renoprotective actions.

Main Methods:

• Administration of genistein to mice treated with cisplatin to assess renal injury markers.
• Evaluation of oxidative stress markers, inflammatory protein expression (ICAM-1, MCP-1), NF-κB activation, and macrophage infiltration in kidney tissues.
• Assessment of apoptosis via p53 regulation in kidney tissues.
• In vitro studies using cisplatin-treated human kidney HK-2 cells to confirm genistein's effect on reactive oxygen species.

Main Results:

• Genistein significantly attenuated cisplatin-induced renal injury in mice.
• Genistein reduced reactive oxygen species (ROS) production and suppressed the expression of ICAM-1 and MCP-1.
• Genistein inhibited nuclear translocation of NF-κB p65, decreased macrophage infiltration, and reduced cisplatin-induced apoptosis by modulating p53.
• Genistein decreased ROS production in cisplatin-treated human kidney HK-2 cells.

Conclusions:

• Genistein demonstrates significant renoprotective effects against cisplatin-induced nephrotoxicity.
• The protective mechanisms involve the mitigation of oxidative stress, inflammation, and apoptosis.
• Genistein and similar compounds hold promise as potential therapeutic agents for preventing chemotherapy-induced kidney damage.